Regeneron and GlaxoSmithKline have joined forces to generate genetic sequence data from the 500,000 volunteers in the UK’s Biobank database. The companies hope the initiative will give insights ...

Now, the emerging practice has joined the Wallpaper* Architects’ Directory 2023, our annual round-up of exciting emerging architecture studios. Its Esplanade House project is a minimalist seaside home ...

The UK government has signed a fourth coronavirus vaccine deal, securing up to 60 million doses of an experimental treatment being developed by drug giants GSK and Sanofi. The government has ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales ...

GSK has confirmed plans to sell its Horlicks business in the UK and close the site where the malted drink is made. As well as shutting the site in Slough, the pharmaceuticals giant said it will ...

The UK company reveals the results from a partner ... Ben Hargreaves examines the reasons supplied by the survey and why GSK is invested in the answers. The emergence of COVID-19 meant that ...

The dynamic architectural practice works between Ukraine, Belgium and the UK with a main office based in south London ... She first wrote for Wallpaper* in 2021, in a series on the new vanguard of ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

Barclays lowered the firm’s price target on GSK (GSK) to 1,450 GBp from 1,550 GBp and keeps an Equal Weight rating on the shares.

GSK GSK0.69%increase; green up pointing triangle shares topped the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S ...